Cover Image

Correction to Beyond MABEL : An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute ( HESI ) Immuno‐Safety Technical Committee ( ITC )

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Clinical Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correction to “Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing”
Published: (2025)

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma
by: Ruben Malmberg, et al.
Published: (2025)

A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
by: Xuewen Ma, et al.
Published: (2024)

Effectiveness and Safety of Reduced‐Dose Prasugrel in an East Asian Population: PRASFIT ‐ ACS Emulation Using National Health Insurance Claims Data
by: Li‐Wen Huang, et al.
Published: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients
by: Eleanor A. Lisbon, et al.
Published: (2025)

Pharmacokinetics and Exposure–Response Analyses to Support Dose Selection of Upadacitinib in Crohn's Disease
by: Sumit Bhatnagar, et al.
Published: (2024)

A User‐Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline
by: Charlotte Koldeweij, et al.
Published: (2024)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
by: Jatinder Kaur Mukker, et al.
Published: (2025)

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates
by: Andrew B. SyBing, et al.
Published: (2025)

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
by: Sharif I. Soleman, et al.
Published: (2024)

Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing
by: Gauri G. Rao, et al.
Published: (2024)

Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
by: Neha Thakre, et al.
Published: (2024)

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib
by: Devasha Redhi, et al.
Published: (2026)

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation
by: Wangda Zhou, et al.
Published: (2025)

Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection
by: Allison M. Claas, et al.
Published: (2024)

Beyond Population‐Level Targets for Drug Concentrations: Precision Dosing Needs Individual‐Level Targets that Include Superior Biomarkers of Drug Responses
by: Thomas M. Polasek, et al.
Published: (2024)

Reinforcement Learning and PK‐PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma
by: Alessandro De Carlo, et al.
Published: (2024)

Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form
by: Vivek Purohit, et al.
Published: (2024)

Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Published: (2024)

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
by: Joseph Burnett, et al.
Published: (2025)

Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia
by: Matthew W. Hruska, et al.
Published: (2024)

Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy
by: Fatima Zahra Marok, et al.
Published: (2024)

Model‐Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC : A QSP Model for Alpelisib and Tipifarnib Combination
by: Jaehee Shim, et al.
Published: (2026)

Correction to “Promise of Quantitative Proteomics in the Qualification of New Approach Methodologies”
Published: (2026)

Assessment of Dosing Strategies for Pediatric Drug Products
by: Zachary L. Taylor, et al.
Published: (2024)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies
by: Rachel K. Scott, et al.
Published: (2026)

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer
by: Emmanuel Chigutsa, et al.
Published: (2026)

Moving the Needle for Oncology Dose Optimization: A Call for Action
by: Karthik Venkatakrishnan, et al.
Published: (2024)

Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future
by: Karen Rowland Yeo, et al.
Published: (2024)

Dosing and Exposure of Vancomycin With Continuous Infusion: A Retrospective Study
by: Judith Y. M. N. Derijks‐Engwegen, et al.
Published: (2024)

Requirements for Phase Lag in First‐In‐Human Trials in India: Proceedings of a Panel Discussion
by: Nusrat Shafiq, et al.
Published: (2026)

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals
by: George S. Q. Tan, et al.
Published: (2025)

Model‐Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations
by: Rashudy F. Mahomedradja, et al.
Published: (2025)

Model‐Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen
by: Peter N. Morcos, et al.
Published: (2024)

Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers
by: Mariam A. Ahmed, et al.
Published: (2024)

Correction to “Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals”
Published: (2024)

Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World
by: Jens Grueger, et al.
Published: (2025)

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data
by: Gaurav Bajaj, et al.
Published: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class ClC‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
by: Titia Q. Ruijs, et al.
Published: (2024)

Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T‐Cell Engagers Development in Oncology
by: Mohamed Elmeliegy, et al.
Published: (2024)